How to make a decision on the choice of therapy for multiple sclerosis with sarcoidosis comorbidity?

References

1. 1.↵
   1. Baghbanian S,
   2. Sahraian M.

   Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis. Iran J Neurol 2018; 17: 129–136.

   OpenUrl
2. 2.↵
   1. Tyshkov C,
   2. Pawate S,
   3. Bradshaw M,
   4. Kimbrough D,
   5. Chitnis T,
   6. Gelfand J, et al.

   Multiple sclerosis and sarcoidosis. Neurol Clin Pract 2019; 9: 218–227.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Kemanetzoglou E,
   2. Andreadou E.

   CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep 2017; 17: 36.

   OpenUrlPubMed
4. 4.↵
   1. Graf J,
   2. Ringelstein M,
   3. Lepka K,
   4. Schaller J,
   5. Quack H,
   6. Hartung H, et al.

   Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. Mult Scler 2018; 24: 1776–1778.

   OpenUrl
5. 5.↵
   1. Zella S,
   2. Kneiphof J,
   3. Haghikia A,
   4. Gold R,
   5. Woitalla D,
   6. Thöne J.

   Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018; 11: 175628641880573.

   OpenUrl